NB 001 - NysnoBio
Alternative Names: NB-001 - NysnoBioLatest Information Update: 28 Aug 2023
At a glance
- Originator NysnoBio
- Class Antidementias; Antiparkinsonians; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Mitochondrial disorders; Parkinson's disease
Most Recent Events
- 17 Jul 2023 Preclinical trials in Alzheimer's disease in USA (Parenteral) (NysnoBio pipeline, July 2023)
- 17 Jul 2023 Preclinical trials in Amyotrophic lateral sclerosis in USA (Parenteral) (NysnoBio pipeline, July 2023)
- 17 Jul 2023 Preclinical trials in Mitochondrial disorders in USA (Parenteral) (NysnoBio pipeline, July 2023)